Prevention of thrombocytopenia using thrombopoietin in high-dose cytarabine treatment of non-Hodgkin lymphoma.

Huang, He; Wang, Zhao; Hong, Huangming; Guo, Chengcheng; Li, Xueying; Zhang, Mengping; Lin, Xun; Fang, Xiaojie; Fu, Xiaohong; Tian, Ying; Li, Shanshan; Liu, Tingzhi; Liang, Chaoyong; Lin, Jia Tian; Shrestha, Dr.Prem Raj; Xiao, Jian; Zhang, Hongyu; Cao, Yabing; Zhai, Linzhu; Lin, Tongyu

doi:10.1200/jco.2014.32.15_suppl.e19532

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data from the thrombopoietic agent arms of 10 studies [ 24 – 26 , 34 , 51 , 57 , 62 , 64 , 68 , 69 , 71 ] and control arms of 6 studies [ 24 – 26 , 57 , 62 , 71 ] were included in the meta-analysis for grade 3/4 thrombocytopenia ( Fig 2 , Table 2 , S4 Fig ). Rates of grade 3/4 thrombocytopenia appeared to be similar for thrombopoietic agents and placebo or no treatment (39.3% vs 34.8%; P = 0.789) ( Fig 2 , Table 2 ).…”

Section: Resultsmentioning

confidence: 99%

Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia

et al. 2022

View full text Add to dashboard Cite

Background Currently, there are no approved options to prevent or treat chemotherapy-induced thrombocytopenia (CIT). We performed a systematic literature review and meta-analysis on use of thrombopoietic agents for CIT. Patients and methods We searched Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, PubMed, EMBASE, ClinicalTrials.gov, and health technology assessments from January 1995 to March 2021 for studies evaluating thrombopoietic agents for CIT, including recombinant human thrombopoietin (rhTPO), megakaryocyte growth and development factor (MGDF), romiplostim, and eltrombopag. Random effects meta-analyses were conducted for efficacy and safety endpoints. Results We screened 1503 titles/abstracts, assessed 138 articles, and abstracted data from 39 publications (14 recombinant human thrombopoietin, 7 megakaryocyte growth and development factor, 9 romiplostim, 8 eltrombopag, and 1 romiplostim/eltrombopag). Random effects meta-analyses of data from multiple studies comparing thrombopoietic agents versus control (comparator, placebo, or no treatment) showed that thrombopoietic agents did not significantly improve chemotherapy dose delays and/or reductions (21.1% vs 40.4%, P = 0.364), grade 3/4 thrombocytopenia (39.3% vs 34.8%; P = 0.789), platelet transfusions (16.7% vs 31.7%, P = 0.111), grade ≥ 2 bleeding (6.7% vs 16.5%; P = 0.250), or thrombosis (7.6% vs 12.5%; P = 0.131). However, among individual studies comparing thrombopoietic agents with placebo or no treatment, thrombopoietic agents positively improved outcomes in some studies, including significantly increasing mean peak platelet counts (186 x 109/L with rhTPO vs 122 x 109/L with no treatment; P < 0.05) in one study and significantly increasing platelet count at nadir (56 x 109/L with rhTPO vs 28 x 109/L with not treatment; P < 0.05) in another study. Safety findings included thrombosis (n = 23 studies) and bleeding (n = 11), with no evidence of increased thrombosis risk with thrombopoietic agents. Conclusion Our analyses generate the hypothesis that thrombopoietic agents may benefit patients with CIT. Further studies with well-characterized bleeding and platelet thresholds are warranted to explore the possible benefits of thrombopoietic agents for CIT.

show abstract

Section: Resultsmentioning

confidence: 99%

Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The morphology of bone marrow and peripheral smears at the cellular level can be significantly changed after administration of cytarabine, and the gravity of this drug toxicity is dose-and time-dependent. Myeloid leukemia patients reported a range of frequencies of anemia, thrombocytopenia, and neutropenia at dosages ranging from 20 mg to 50 g/m 2 day (Table 2) [45][46][47][48][49][50][51]. Gemcitabine is a similar drug to cytarabine but is used to treat various solid tumor malignancies.…”

Section: Hematological Toxicities Of Anticancer Nucleoside Drugsmentioning

confidence: 99%

Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective

Ali

Raj

Kaur

et al. 2022

Cancers

View full text Add to dashboard Cite

Anticancer nucleoside analogs produce adverse, and at times, dose-limiting hematological toxicities that can compromise treatment efficacy, yet the mechanisms of such toxicities are poorly understood. Recently, cellular nucleoside transport has been implicated in normal blood cell formation with studies from nucleoside transporter-deficient mice providing additional insights into the regulation of mammalian hematopoiesis. Furthermore, several idiopathic human genetic disorders have revealed nucleoside transport as an important component of mammalian hematopoiesis because mutations in individual nucleoside transporter genes are linked to various hematological abnormalities, including anemia. Here, we review recent developments in nucleoside transporters, including their transport characteristics, their role in the regulation of hematopoiesis, and their potential involvement in the occurrence of adverse hematological side effects due to nucleoside drug treatment. Furthermore, we discuss the putative mechanisms by which aberrant nucleoside transport may contribute to hematological abnormalities and identify the knowledge gaps where future research may positively impact treatment outcomes for patients undergoing various nucleoside analog therapies.

show abstract

Prevention of thrombocytopenia using thrombopoietin in high-dose cytarabine treatment of non-Hodgkin lymphoma.

Cited by 2 publications

References 0 publications

Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia

Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia

Solute Carrier Nucleoside Transporters in Hematopoiesis and Hematological Drug Toxicities: A Perspective

Contact Info

Product

Resources

About